Repatha (Evolocumab): Second PCSK9 Inhibitor Approved by the FDA for Patients with Familial Hypercholesterolemia.
Loretta
L
Fala
Eur Heart J. 2013 Dec;34(45):3478-90a
23956253
Lancet. 2015 Jan 24;385(9965):341-50
25282520
Lancet. 2015 Jan 24;385(9965):331-40
25282519
N Engl J Med. 2015 Apr 16;372(16):1500-9
25773607
JAMA. 2014 May 14;311(18):1870-82
24825642